People have been comparing ACAD and KERX for a long time, I was long KERX made money now I am going to ACAD. They won and have the potential to make more money than we can. The FDA waived their secondary P3 trial, what you think they do that all the time? Name one other company the FDA told them, don't worry about doing a second confirmatory P3 Trial and then tell me that drug did not get approved. There are hundreds of biotech stocks, is there one out there? No there isn't. So hey it happens, they're winning and I want to get in now so I am not paying $30 a share a year from now. Good Luck!
I think the potential is similar for both stocks, but I think the approval process will be easier and faster for Keryx due to it's better patient tolerance, lower side effects, tremendous cost savings, and fairly simple chemical compound. Acad also said that they have other sub-studies to get through first before they will even submit anything to the FDA for review, and that will add additional time to their approval. Keryx will most likely be up 100% from here in 12-18 months---or sooner with faster approval(Japan) and positive predialysis test results--along with the likelihood of partnership or buyout. Acad will most likely rise a little slower.
Sentiment: Strong Buy
Long both ACAD and KERX here.....Think both will do well. KERX is being accumulated at these levels. ACAD is better takeout candidate based on assets for longer term but think KERX may surprise with partnership news soon imo. Check out INSM also - my largest holding now- think INSM will be big winner in next few months. Looking for INSM to hit $25 at end of summer....